Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
Coffee May Reduce Dementia Risk, But Only If You Drink This Type
In other words, it seems that sugar-free caffeinated coffee seemed to produce the links the scientists noticed. Participants ...
'Silent killer' habit at night may increase your risk of three chronic diseases
Dr Eric Berg DC has warned suffering from the condition every night could put you more at risk of several chronic diseases ...
pharmaphorum1h
EMA experts will look again at Leqembi's safety data
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
Night-time habit 'nobody talks about' linked to diabetes, poor immune system and more
Dr Eric Berg DC has shared 'hidden dangers' and numerous health risks of the problem that affects many at night ...
studyfinds2h
Why being a ‘bingo night’ regular could buy your brain an extra 5 years
Going out to restaurants, playing bingo, visiting friends, or attending religious services could give you extra years of healthy brain function, according to new research from Rush University Medical ...
Strictly's Arlene Phillips 'devastated' as she makes dementia statement
Clinical trials have demonstrated that the drug can delay deterioration by four to six months, targeting the beta-amyloid protein in the brain. Another medication, donanemab, has received approval but ...
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...
BioArctic stock sinks on EU regulatory concerns
Despite the regulatory setback, BioArctic's partner Eisai has stated that the safety profile of lecanemab reported in clinical practice in the United States, Japan, and other countries is consistent ...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher ...